The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Documenting the complete resolution rates of venous thromboemboli (VTE) with the factor Xa inhibitor fondaparinux sodium (FS) in patients with cancer.
D. R. Budman
No relevant relationships to disclose
M. F. Barginear
No relevant relationships to disclose
R. J. Gralla
No relevant relationships to disclose
T. P. Bradley
No relevant relationships to disclose
I. Shapira
No relevant relationships to disclose
N. J. Nier-Shoulson
No relevant relationships to disclose
C. R. Greben
No relevant relationships to disclose
M. Akerman
No relevant relationships to disclose
M. Lesser
No relevant relationships to disclose